Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal

Christos Papageorgiou1, Flora Zagouri1, Konstantinos Tampakis1

  • 1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Insights

Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with hormonal therapy increase vascular inflammation and blood pressure in metastatic breast cancer patients. Both CDK 4/6 inhibitors and everolimus treatments promote left ventricle remodeling.

Area of Science:

  • Cardiovascular Medicine
  • Oncology
  • Radiology

Background:

  • Chemotherapy for breast cancer can cause vascular dysfunction and cardiovascular risks.
  • Metastatic breast cancer patients face significant cardiovascular challenges during treatment.

Purpose of the Study:

  • To assess cardiovascular burden and vascular inflammation in metastatic breast cancer patients.
  • To compare the effects of CDK 4/6 inhibitors versus everolimus on cardiovascular parameters.

Main Methods:

  • Echocardiography for relative wall thickness (RWT) and left ventricle mass (LVM).
  • 24-h ambulatory blood pressure monitoring.
  • 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) for aortic uptake (TBR).

Main Results:

  • CDK 4/6 inhibitors significantly increased 24-h systolic and diastolic blood pressure and aortic inflammation (TBR).
  • Everolimus showed stable blood pressure and aortic TBR compared to CDK 4/6 inhibitors.
  • Both regimens led to detrimental effects on RWT and LVM, indicating left ventricle remodeling.

Conclusions:

  • CDK 4/6 inhibitors plus hormonal treatment elevate vascular inflammation and blood pressure more than everolimus plus hormonal treatment.
  • Both therapeutic strategies contribute to left ventricle remodeling in metastatic breast cancer patients.